Monitoring response and resistance to treatment in chronic myeloid leukemia
S Assouline, JH Lipton - Current Oncology, 2011 - mdpi.com
Chronic myeloid leukemia (CML) results from expression of the constitutive tyrosine kinase
activity of the Bcr-Abl oncoprotein. Imatinib, a tyrosine kinase inhibitor (TKI), is highly …
activity of the Bcr-Abl oncoprotein. Imatinib, a tyrosine kinase inhibitor (TKI), is highly …
[HTML][HTML] Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic …
RA Larson, BJ Druker, F Guilhot, SG O'Brien… - Blood, 2006 - Elsevier
A total of 551 pts with newly diagnosed CML-CP received imatinib (IM) 400 mg orally once
daily as part of the IRIS study (O'Brien et al, NEJM 2003). We now summarize the correlation …
daily as part of the IRIS study (O'Brien et al, NEJM 2003). We now summarize the correlation …
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients
O Frank, B Brors, A Fabarius, L Li, M Haak, S Merk… - Leukemia, 2006 - nature.com
Although the selective tyrosine kinase inhibitor imatinib is successfully used in the treatment
of chronic myeloid leukemia (CML), inherent mechanisms confer primary resistance to …
of chronic myeloid leukemia (CML), inherent mechanisms confer primary resistance to …
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic …
SK Sohn, SJ Oh, BS Kim, HM Ryoo… - Leukemia & …, 2011 - Taylor & Francis
To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or
molecular responses, we measured trough IM levels in patients with chronic myeloid …
molecular responses, we measured trough IM levels in patients with chronic myeloid …
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate
ME O'Dwyer, MJ Mauro, C Blasdel, M Farnsworth… - Blood, 2004 - ashpublications.org
We followed 141 patients treated with imatinib mesylate (> 300 mg) for chronicphase chronic
myelogenous leukemia (CML) following failure of treatment with interferon. During 12 …
myelogenous leukemia (CML) following failure of treatment with interferon. During 12 …
[HTML][HTML] Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy
G Etienne, S Dulucq, FE Nicolini, S Morisset… - …, 2014 - ncbi.nlm.nih.gov
Sustained imatinib treatment in chronic myeloid leukemia patients can result in complete
molecular response allowing discontinuation without relapse. We set out to evaluate the …
molecular response allowing discontinuation without relapse. We set out to evaluate the …
[PDF][PDF] Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia
D White, V Saunders, A Grigg, C Arthur… - Journal of clinical …, 2007 - Citeseer
Purpose Intrinsic sensitivity to imatinib, based on measurement of inhibitory concentration
50% for imatinib, is variable in untreated patients with chronic myeloid leukemia (CML). This …
50% for imatinib, is variable in untreated patients with chronic myeloid leukemia (CML). This …
Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients
FE Nicolini, S Dulucq, L Boureau, P Cony-Makhoul… - Clinical Cancer …, 2019 - AACR
Purpose: Tyrosine kinase inhibitor (TKI) discontinuation is an emerging goal in chronic
myelogenous leukemia (CML) management and several studies have demonstrated the …
myelogenous leukemia (CML) management and several studies have demonstrated the …
[PDF][PDF] Hematological and molecular response evaluation of CML patients on imatinib
Abstract Background: The BCR-ABL tyrosine kinase is a well-validated therapeutic target in
Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase …
Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase …
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
S Picard, K Titier, G Etienne, E Teilhet, D Ducint… - Blood, 2007 - ashpublications.org
Using high-performance liquid chromatography–tandem mass spectrometry, we assessed
trough imatinib plasma levels in 68 patients with chronic myeloid leukemia (CML) who …
trough imatinib plasma levels in 68 patients with chronic myeloid leukemia (CML) who …